Category: GLOBE-NEWSWIRE

New, secure U.S. environment launches with NIST SP 800-171 assessment in anticipation of future CMMC certification

BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) — Anaqua, the leading provider of innovation and intellectual property (IP) management technology, today announced the launch of AnaquaGov, providing U.S. defense contractors and all other clients handling U.S. CUI (Controlled Unclassified Information) with a specialized environment to manage their highly sensitive IP data.

In making the announcement, Anaqua confirmed that the AnaquaGov enclave fully meets NIST SP 800-171 compliance requirements—the strict standards set by the U.S. National Institute of Standards and Technology for safeguarding sensitive information on federal contractors’ IT systems and networks. This follows a review and validation of AnaquaGov by Schellman & Company, LLC, a leading CMMC third-party assessment organization (C3PAO). For this offering, Anaqua operates the AQX^® IP Management System in the AnaquaGov enclave.

The development marks a significant step forward in Anaqua’s objective for AnaquaGov to obtain Cybersecurity Maturity Model Certification (CMMC)—the new standard designed to improve the cybersecurity readiness of businesses that work with the U.S. Department of Defense (DoD)—once the standard is finalized, and certifications are generally available.

Anaqua CEO Bob Romeo said: “At Anaqua, we pride ourselves on the security of our IP platform and the integrity of our data management, and we are delighted to have that further validated by Schellman. AnaquaGov represents another layer of security for our clients managing the most sensitive U.S. data and complements our ISO 27001, ISO 9001 and SOC 2 Type 2 certifications and global security programs. Through AnaquaGov, we now support client entities in managing their IP portfolios to the levels of security required by DoD. We are looking forward to CMMC certifications being available in the near future and we are ready.”

Anaqua CIO Erik Bailey further explained: “Many companies today that manage Controlled Unclassified Information—frequently under export control regulations—simply do not have access to a secure platform to perform their duties in a compliant manner. Through AQX hosted within the AnaquaGov enclave, we provide a comprehensive solution to entities that have, or suspect they have, CUI. These clients can carry out their responsibilities, securely, in an environment that has been independently assessed against stringent NIST controls and that is aligned with upcoming CMMC requirements.”

About Anaqua
Anaqua, Inc. is a premier provider of integrated intellectual property (IP) management technology solutions and services for corporations and law firms. Its IP management software solutions, AQX^® and PATTSY WAVE^®, both offer best practice workflows with big data analytics and tech-enabled services to create an intelligent environment designed to inform IP strategy, enable IP decision-making, and streamline IP operations, tailored to each segment’s need. Today, nearly half of the top 100 U.S. patent filers and global brands, as well as a growing number of law firms worldwide use Anaqua’s solutions. Over one million IP executives, attorneys, paralegals, administrators, and innovators use the platform for their IP management needs. The company’s global operations are headquartered in Boston, with offices across the U.S., Europe, Asia, and Australia. For additional information, please visit anaqua.com, or on Anaqua’s LinkedIn.

Company Contact:
Amanda Glagolev
Director, Communications
Anaqua
617-375-5808
aglagolev@anaqua.com

GlobeNewswire Distribution ID 9037623

King Faisal Specialist Hospital and Research Centre – Riyadh

King Faisal Specialist Hospital and Research Centre – Riyadh

RIYADH, Saudi Arabia, Feb. 15, 2024 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSH&RC) has once again secured its position for the second consecutive year as a global leader in healthcare and number one in the Middle East and Africa, ranking 20^th globally among the leading healthcare institutions in the Brand Finance Global Top 250 Hospitals 2024 report. KFSH&RC continues to stand at the forefront both locally and regionally, underlining its commitment to delivering world-class patient-centric healthcare and medical innovation.

Leading the way, KFSH&RC is joined by King Saud Medical City, King Khalid University Hospital, National Guard Health Affairs, and King Fahd Medical City, all ranked among the top 100 globally. While King Fahd University Hospital and King Abdullah Medical City rank between 101 and 250. This assessment is based on insights from thousands of healthcare practitioners across over 30 countries.

The remarkable performance of KFSH&RC in this global ranking is a testament to the Kingdom’s healthcare transformation goals and the transformative impact of Vision 2030, reflected through the continuous improvement of healthcare services and the pursuit of technological advancements across the Kingdom for a healthier and thriving nation.

Brand Finance, founded in 1996, annually evaluates over 500 hospitals worldwide, utilizing more than 30 performance indicators encompassing healthcare, research centres, and education to support science-based strategic decision making.

King Faisal Specialist Hospital & Research Centre stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced hub for medical research and education. Through strategic partnerships with prominent local, regional, and international institutions, the hospital is dedicated to advancing medical technologies and elevating the standards of healthcare worldwide.

About King Faisal Specialist Hospital & Research Centre (KFSH&RC):

King Faisal Specialist Hospital & Research Centre (KFSH&RC) stands as a leading healthcare institution in the Middle East, envisioned to be the optimal choice for every patient seeking specialized healthcare. The hospital boasts a rich history in the treatment of cancers, cardiovascular diseases, organ transplantation, neurosciences, and genetics.

In 2024, “Brand Finance” ranked King Faisal Specialist Hospital & Research Centre as the top academic medical centre in the Middle East and Africa, and among the top 20 globally. Additionally, in 2022, it was recognized as one of the leading global healthcare providers by Newsweek magazine.

As part of Saudi Vision 2030, a royal decree was issued on December 21, 2021, to transform the hospital into an independent, non-profit, government-owned entity, paving the way for a comprehensive transformation program aimed at achieving global leadership in healthcare through excellence and innovation.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1cab7add-5d3e-482c-bd5b-cc8856cf7875

CONTACT INFORMATION 

For more information please contact:

Mr. Essam Al-Zahrani, Acting Head of Media Affairs, 0555254429

Mr. Abdullah Al-Awn, Media Coordination Officer, 0556294232

GlobeNewswire Distribution ID 9038044

Amsterdam, Feb. 15, 2024 (GLOBE NEWSWIRE) — STX Group, a leading global firm in environmental commodities trading and climate finance, today announces the financing partnership with BioValue, a major Dutch biomethane producer, for the construction and development of the Groengas Cothen biomethane plant. The new plant adds at least 80GWh of renewable natural gas capacity per year. This strategic move is aligned with STX Group’s mission to promote the energy transition and underscores the redefinition of market dynamics aimed at boosting project development in the renewable energy space.

The financing by STX Group ensures BioValue access to key capital but also provides flexibility, avoiding potential constraints from fixed offtake prices. Collaborating with Nationaal Groenfonds as the junior financier, STX Group goes beyond traditional offtake agreements: unlike traditional banking institutions, this financing model provides BioValue with exposure to the developing biomethane market, contributing to their strategic goals and long-term success.

“This agreement marks a significant milestone in the biomethane sector and showcases our ability to pioneer novel financing solutions,” says Sead Keric, Managing Partner of Renewable Gas at STX Group.  “By combining BioValue’s operational expertise with our climate finance capabilities, we empower biomethane producers to focus on what they do best while addressing development challenges. In light of the developing nature of the biomethane market and the illiquid, less transparent markets, there is a pressing need for alternative financing solutions.”

“As a major biomethane actor running multiple plants in the Netherlands, we are determined to realize much-needed new capacity in line with Dutch biomethane targets and European Fit for 55 goals,” said Ids Schaap, Managing Director and Founder of BioValue. “Our commitment to reducing CO2 emissions and minimizing environmental impact aligns seamlessly with STX Group’s mission to drive sustainable practices in the renewable energy sector.”

The latest EBA report revealed European biomethane production rose by 20% in 2022 over the previous year. However, the EU dependency on natural gas imports went from 83% to 97%. Amidst the global push for sustainability, momentum is building in the biomethane sector, marked by surging industrial demand and capacity despite project development challenges.

The European Commission established a goal aiming to achieve 35 bcm of sustainable biomethane production by 2030, as an integral part of REPowerEU. “While we welcome the recent European Parliament’s recognition of biomethane contribution to the decarbonization of the transportation sector, establishing a fair and comprehensive legislative framework for accounting the role of renewable fuels would bring additional benefits to the market,” Keric commented.

About STX Group

STX Group is a leading global environmental commodity trader and climate solutions provider. For over 25 years, our teams continue to be at the forefront of the global transition towards a low-carbon economy. Leveraging our long-standing expertise in accurately pricing pollution and emissions, we help cultivate trust in market-based solutions to the decarbonized economy.

Our trading and corporate climate solutions offerings ensure capital flows to thousands of projects that make the world a greener place, while providing corporations with certified proof-points of their contributions to environmental progress.

Headquartered in Amsterdam with offices in 13 countries worldwide, our global team, inclusive of Vertis and Strive, comprises of over 500 employees of 60+ nationalities.

For more information, please visit https://stxgroup.com/

About BioValue

BioValue is a pioneer in the Dutch biogas market with multiple biogas installations throughout the country. By producing sustainable green gas from organic waste, the use of fossil gas can be reduced which leads to a reduction in the CO2 levels in the atmosphere.

BioValue’s vision is to grow in impact by producing as much renewable energy as possible. Currently, the strategic focus is set on Bio-LNG production. BioValue is actively engaged in the development of the world’s largest bio-LNG installation located in the dynamic port of Amsterdam.

The company is expected to grow in the coming year to a projected production of more than 300.000 MWh of Green Gas and Bio-LNG per year.

Attachments

• STX Group Announces Unique Financing Partnership With BioValue for Dutch Biomethane Plant
• STX Group Announces Unique Financing Partnership With BioValue for Dutch Biomethane Plant

Jaime Santisteban
STX Group
+33745291715
jaime.santisteban@stxgroup.com

GlobeNewswire Distribution ID 9036937

Continued Progress Earns Financing to Accelerate Commercial Growth and Advancing Pipeline

Marlton, NJ, Feb. 14, 2024 (GLOBE NEWSWIRE) — Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure (HF), is proud to announce that it raised $136 million in financing to accelerate investment in global commercialization, technology, product innovation, and further development of clinical evidence. The financing was led by Perceptive Advisors, Redmile Group, Alger, and Hobart Healthcare. This substantial investment reflects investor confidence in, and commitment to, the company’s vision and expansion.

“This round of funding will accelerate our business, both commercially and with our pipeline of advanced technology innovation,” said Jason Spees, CEO of Impulse Dynamics. “We continue to make commercial progress globally with more than 9,000 heart failure patients implanted with CCM^® therapy and millions more who can benefit. We are also getting closer to significantly impacting the implantable cardioverter defibrillator (ICD) market with successful enrollment in our INTEGRA-D clinical trial on the Optimizer^® Integra CCM-D^® System. Most patients who currently receive a standard ICD get lifesaving benefits from the defibrillator but still struggle with HF symptoms. With CCM-D, these patients will be able to get the lifesaving benefits of a defibrillator combined with HF symptom relief from CCM in one device.”

The funding will fuel commercialization efforts, develop future product pipelines, and support groundbreaking clinical trials such as the INTEGRA-D and AIM HIGHer clinical trials. The INTEGRA-D trial is a multicenter study evaluating the combination of CCM and ICD therapy in a single device – the Optimizer Integra CCM-D System. The AIM HIGHer clinical trial is a multicenter study with the objective to evaluate the safety and efficacy of CCM therapy in patients with symptomatic HF with an ejection fraction (EF) of 40 to 60 percent (inclusive). The trial is currently in its initial enrollment phase and has generated significant attention, feedback, and excitement among experts in HF.

“We are thrilled by the ongoing support from top-tier investment groups for Impulse Dynamics,” said Shlomi Nachman, Chairman of the Board. “Those investments will accelerate the cadence of innovation and market awareness in CCM therapy. I am extremely confident in Impulse Dynamics’ strong leadership and their excellent teams to enhance even further the developments and commercial activities of CCM therapy for the benefit of millions of HF patients worldwide.”

The Optimizer Smart Mini system delivers CCM therapy — the company’s proprietary technology — to the heart, providing an important treatment option for the millions of patients suffering from heart failure. CCM therapy is designed to significantly improve heart contraction, allowing more oxygen-rich blood to be pushed out through the body.[1] CCM therapy is indicated to improve 6-minute hall walk, quality of life, and functional status of NYHA Class III HF patients who remain symptomatic despite guideline directed medical therapy, are not indicated for CRT, and have a left ventricular ejection fraction ranging from 25 to 45 percent.

About Impulse Dynamics
Impulse Dynamics is dedicated to advancing the treatment of heart failure for patients and the healthcare providers who care for them. The company pioneered its proprietary CCM therapy, which uses the Optimizer technology platform to improve quality of life in HF patients. CCM therapy is delivered through the Optimizer system, which includes an implantable pulse generator (IPG) implanted in a minimally invasive procedure and approved for commercial use in the United States and 44 countries worldwide. More than 9,000 patients have received the therapy as part of clinical trials and real-world use, where it is proven to be safe and effective for heart failure patients with debilitating symptoms who otherwise have few effective options available to them. To learn more, visit www.ImpulseDynamics.com, or follow the company on LinkedIn, X (formerly Twitter), and Facebook.

[1] European Journal of Heart Failure (2021) doi:10.1002/ejhf.2202

Scott Way, Executive Vice President, General Counsel
Impulse Dynamics
856-434-7906
sway@impulsedynamics.com

Rohan More, Global Vice President, Marketing
Impulse Dynamics
856-642-9933
rmore@impulsedynamics.com

GlobeNewswire Distribution ID 9036957

Independent study finds 228% ROI over three years with implementation of Quantexa’s Decision Intelligence Platform

5 Key Benefits and how much was saved with Quantexa’s Decision Intelligence Platform

5 Key Benefits and how much was saved with Quantexa’s Decision Intelligence Platform

LONDON, Feb. 13, 2024 (GLOBE NEWSWIRE) — Organizations need a trusted data foundation to enable effective decisions that allow them to operate efficiently, plan for the future, and grow. Yet many organizations continue to struggle with a lack of a single customer view, duplicated records, inefficient processes, and ineffective results.

Today, Quantexa has published The Total Economic Impact of The Quantexa Decision Intelligence Platform study, providing business value justification analysis to help organizations understand the financial impact of their technology investment. Quantexa commissioned Forrester Consulting to interview six customers in data-related leadership roles across banking, telecommunications, and the public sector to examine the potential return on investment and other benefits enterprises can realize with Decision Intelligence.

In this case, the study outlines a breakdown of the quantitative and qualitative benefits, potential financial impacts, and associated risks of implementing Quantexa’s Decision Intelligence Platform for a composite organization based on the interviewed customers.

Customer benefits included:

• Three-year 228% Return on Investment
• Payback period less than eight months
• Estimated $34.8M Net Present Value in customer benefits over three years

5 Key Benefits and how much was saved with Quantexa’s Decision Intelligence Platform

A Global Head of Financial Crime Detection, Financial Services customer stated that, “Quantexa provides us the ability to source and fuse data in a flexible and scalable ecosystem and it provides a multi-dimensional view of the customer almost in real time. It enables us to use this model to reduce risk and to reduce the amount of infrastructure and human resources and monetize data assets.”

For more information on the Total Economic Impact of Quantexa’s Decision Intelligence Platform, please download the full 2024 study.

About Quantexa

Quantexa is a global data and analytics software company pioneering Decision Intelligence that empowers organizations to make trusted operational decisions by making data meaningful. Using the latest advancements in big data and AI, Quantexa’s Decision Intelligence platform uncovers hidden risk and new opportunities by providing a contextual, connected view of internal and external data in a single place. It solves major challenges across data management, KYC, customer intelligence, financial crime, risk, fraud, and security, throughout the customer lifecycle.

The Quantexa Decision Intelligence Platform enhances operational performance with over 90% more accuracy and 60 times faster analytical model resolution than traditional approaches. Founded in 2016, Quantexa now has more than 675 employees and thousands of users working with billions of transactions and data points across the world. The company has offices in London, Dublin, Brussels, Malaga, UAE, New York, Boston, Toronto, Sydney, Melbourne, and Tokyo.

Media Enquiries 

C: Stephanie Crisp, Fight or Flight
E: Quantexa@fightorflight
OR
C: Adam Jaffe, SVP of Corporate Marketing
T: +1 609 502 6889
E: adamjaffe@quantexa.com

OR
E: RapidResponse@quantexa.com

An image accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/70409264-cd05-40a7-b809-66bbe5ff8e7e

GlobeNewswire Distribution ID 1000913213